[Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].

Abstract

Objective: Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) with dual effects of anti-proliferation and anti-angiogenesis. Phase Ⅰ clinical trials showed anlotinib was well tolerated and had therapeutic effects on a variety of tumors. The aim of this study is to explore the safety and efficacy of anlotinib in the treatment of metastatic renal cell carcinoma. Methods: Between January 2014 and November 2015, a single-center data was obtained from a phase Ⅱ clinical study of anlotinib versus sunitinib on advanced renal cell carcinoma and a phase Ⅱ clinical study of anlotinib on advanced renal cell carcinoma which failed to respond to TKI treatment. Kaplan-Meier method was used for survival analysis, while Log-rank test was used to compare the survival rates. Results: A total of 36 patients with advanced renal cell carcinoma were enrolled in this study, including 19 patients without any target drug treatment, 12 patients with sunitinib treatment and 5 patients with sorafenib treatment. The median number of treatment cycle was 16. Partial response (PR) was obtained in 11 patients (30.6%) and stable disease (SD) was obtained in 24 patients (66.7%). The disease control rate (DCR) was 97.2%. The median progression free survival (PFS) was 12.6 months, the 1-year survival rate was 80.6%, and the median survival time was 22.2 months. Up to the follow-up deadline, 3 patients still received treatment, the PFSs were 52.6 months, 65.0 months, and 66.7 months. The most common treatment-related adverse events of grade 3 or 4 included hypertension (19.4%), hand-foot skin reaction (11.1%), proteinuria (5.6%) and anemia (5.6%). Conclusions: Anlotinib shows good anti-tumor activity and is generally well-tolerated in the treatment of advanced renal cell carcinoma. The adverse reactions of anlotinib are milder than sunitinib or pazopanib.

• Authors: Y Song, Chi Yihebali, L Yang, C X Cui, W Zhang, Y K Sun, C X Du, A P Zhou, J W Wang
• Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] (Zhonghua Zhong Liu Za Zhi) Vol. 42 Issue 9 Pg. 765-770 (Sep 23 2020) ISSN: 0253-3766 [Print] China
• PMID: 32988160 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Indoles
• Quinolines
• anlotinib

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (drug therapy)
• Disease-Free Survival
• Follow-Up Studies
• Humans
• Indoles (therapeutic use)
• Kidney Neoplasms (drug therapy)
• Quinolines (therapeutic use)
• Treatment Outcome